Joseph Burzynski

New York City Department of Health and Mental Hygiene

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence”.

In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.44210

N/A

2.0DataRank · unranked

46 citations

Joan M. Mangan, Chee Kin Lam, Michelle Macaraig, Marco M. Salerno, B. Rey deCastro +31 more

Challenges associated with electronic and in-person directly observed therapy during a randomized trial

The International Journal of Tuberculosis and Lung Disease(2023)10.5588/ijtld.22.0583

N/A

0.205DataRank · unranked

2 citations

Joseph Burzynski, B. Rey deCastro, M. M. Salerno, Chee Kin Lam, Michelle Macaraig +9 more

Adverse events among persons with TB using in-person vs. electronic directly observed therapy

The International Journal of Tuberculosis and Lung Disease(2023)10.5588/ijtld.22.0594

N/A

0DataRank · unranked

1 citations

Joseph Burzynski, Joan M. Mangan, A. Ross Hill, B. Rey deCastro, Neela D. Goswami +5 more

National Tuberculosis Coalition of America (NTCA) Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings

Clinical Infectious Diseases(2024)10.1093/cid/ciae199

N/A

0DataRank · unranked

30 citations

Zoe Dansky, Ruvandhi R. Nathavitharana, H Behm, Shaka Brown, Lana Dov +11 more

Community-Based Tuberculosis Isolation Decisions Require Individualization Based on Effectiveness and Duration of Treatment, Community Risks, and Patient Harms

Clinical Infectious Diseases(2024)10.1093/cid/ciae608

N/A

0DataRank · unranked

0 citations

Ruvandhi R. Nathavitharana, Joseph Burzynski, Maunank Shah

Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen

The International Journal of Tuberculosis and Lung Disease(2025)10.5588/ijtld.24.0616

N/A

0DataRank · unranked

4 citations

Grace Gao, M. M. Salerno, MI Whitehead, Dominique Juste, C. C. Buchanan +7 more

Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.108075

N/A

0DataRank · unranked

0 citations

Kelly E. Dooley, Wendy Carr, Jason E. Stout, Eric Nuermberger, Patrick Phillips +22 more

Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease

Clinical Infectious Diseases(2023)10.1093/cid/ciad312

N/A

0DataRank · unranked

46 citations

Marcos C. Schechter, David Ashkin, Charles A. Peloquin, J. Peter Cegielski, Barbara B Andrino +95 more